JNPMEDI Attends 2022 European Oncology Society (ESMO) congress.

01 Sep 2022 · 4 minutes read

JNPMEDI Attends 2022 European Oncology Society (ESMO) congress from September 9 to 13.

2022 ESMO

JNPMEDI attends the 2022 European Society for Medical Oncology (ESMO) Congress, an annual academic conference of the 2022 European Society for Oncology, for five days from September 9 to 13.

ESMO Congress is the world's largest clinical oncology institute where global anti-cancer treatment experts share clinical trends and treatment development trends, and in 2021, only online, with 23,000 registered. The 2022 ESMO Congress, which marks its 48th anniversary this year, is expected to be hotter than any other year as it is a face-to-face event held in a long time.

JNPMEDI was selected as one of the delegations of the National Clinical Trial Support Foundation (KoNECT), which consists of clinical trial-related companies and institutions and will participate in the ESMO Congress on behalf of Korea. JNPMEDI plans to meet various companies participating in ESMO Congress and actively promote products as a leading clinical trial data solution company in Korea for Decentralized Clinical Trials (DCTs), which is a global trend.


Your Partner for a Successful Journey

JNPMEDI has been putting effort on bringing disruption on healthcare industry via integrating digital technologies to clinical research & trial operations.